ATE447565T1 - Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen - Google Patents

Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen

Info

Publication number: ATE447565T1
Authority: AT; Austria
Prior art keywords: spiro; inflammatory agents; compounds suitable; hydantoin compounds; hydantoin
Prior art date: 2001-10-01

Application number

AT02800414T

Other languages

English (en)

Inventor

T G Murali Dhar

Dominique Potin

Magaili Jeannine Blandine Maillet

Michele Launay

Eric Antoine Nicolai

Edwin J Iwanowicz

Original Assignee

Bristol Myers Squibb Co

Cerep Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-01

Filing date

2002-09-30

Publication date

2009-11-15

2002-09-30 Application filed by Bristol Myers Squibb Co, Cerep Sa filed Critical Bristol Myers Squibb Co

2009-11-15 Application granted granted Critical

2009-11-15 Publication of ATE447565T1 publication Critical patent/ATE447565T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Transplantation (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)

AT02800414T 2001-10-01 2002-09-30 Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen ATE447565T1 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US32636101P	2001-10-01	2001-10-01
US35411302P	2002-02-04	2002-02-04
US40025902P	2002-08-01	2002-08-01
PCT/US2002/031283 WO2003029245A1 (en)	2001-10-01	2002-09-30	Spiro-hydantoin compounds useful as anti-inflammatory agents

Publications (1)

Publication Number	Publication Date
ATE447565T1 true ATE447565T1 (de)	2009-11-15

Family

ID=27406458

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02800414T ATE447565T1 (de)	2001-10-01	2002-09-30	Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen

Country Status (24)

Country	Link
US (4)	US6977267B2 (de)
EP (1)	EP1432700B1 (de)
JP (1)	JP4394442B2 (de)
KR (1)	KR20040041649A (de)
CN (1)	CN1596253A (de)
AR (1)	AR036663A1 (de)
AT (1)	ATE447565T1 (de)
BR (1)	BR0213025A (de)
CA (1)	CA2462112A1 (de)
DE (1)	DE60234264D1 (de)
ES (1)	ES2339107T3 (de)
GE (1)	GEP20063767B (de)
HK (1)	HK1063467A1 (de)
HR (1)	HRP20040311A2 (de)
HU (1)	HUP0402338A3 (de)
IL (1)	IL160990A0 (de)
IS (1)	IS7197A (de)
MX (1)	MXPA04002993A (de)
NO (1)	NO20041339L (de)
NZ (1)	NZ531870A (de)
PE (1)	PE20030845A1 (de)
PL (1)	PL369337A1 (de)
RS (1)	RS26604A (de)
WO (1)	WO2003029245A1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1608317B1 (de) *	2003-03-25	2012-09-26	Takeda Pharmaceutical Company Limited	Dipeptidylpeptidase-hemmer
US7700583B2 (en)	2003-04-11	2010-04-20	High Point Pharmaceuticals, Llc	11β-hydroxysteroid dehydrogenase type 1 active compounds
ATE482747T1 (de) *	2003-04-11	2010-10-15	High Point Pharmaceuticals Llc	Neue amide derivate und deren pharmazeutische verwendungen
US7169926B1 (en)	2003-08-13	2007-01-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7678909B1 (en)	2003-08-13	2010-03-16	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
US7470700B2 (en) *	2003-08-13	2008-12-30	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2005030751A2 (en) *	2003-09-08	2005-04-07	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP2007505121A (ja) *	2003-09-08	2007-03-08	武田薬品工業株式会社	ジペプチジルぺプチダーゼ阻害剤
US7199125B2 (en)	2003-10-02	2007-04-03	Bristol-Myers Squibb Company	Spiro-cyclic compounds useful as anti-inflammatory agents
JP5105578B2 (ja)	2003-11-05	2012-12-26	サーコードバイオサイエンスインコーポレイテッド	細胞接着のモジュレーター
CA2550447A1 (en)	2003-12-19	2005-07-07	The Regents Of The University Of California	Methods and materials for assessing prostate cancer therapies
NZ550102A (en)	2004-02-24	2010-10-29	Univ California	Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
US7732446B1 (en)	2004-03-11	2010-06-08	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
AU2004318013B8 (en) *	2004-03-15	2011-10-06	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
JP2008501714A (ja) *	2004-06-04	2008-01-24	武田薬品工業株式会社	ジペプチジルペプチダーゼインヒビター
CN102827082B (zh)	2004-07-01	2015-01-07	第一三共株式会社	具有pde7抑制活性的噻吩并吡唑衍生物
WO2006019965A2 (en)	2004-07-16	2006-02-23	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7375237B2 (en)	2004-08-18	2008-05-20	Bristol-Myers Squibb Company	Pyrrolizine compounds useful as anti-inflammatory agents
TW200616634A (en) *	2004-10-01	2006-06-01	Bristol Myers Squibb Co	Crystalline forms and process for preparing spiro-hydantoin compounds
US8110581B2 (en) *	2004-11-10	2012-02-07	Incyte Corporation	Lactam compounds and their use as pharmaceuticals
KR101368228B1 (ko) *	2004-11-10	2014-02-27	인사이트 코포레이션	락탐 화합물 및 약제로서의 이의 용도
US20060142319A1 (en) *	2004-12-14	2006-06-29	Bang-Chi Chen	Pyridyl-substituted spiro-hydantoin crystalline forms and process
US7186727B2 (en) *	2004-12-14	2007-03-06	Bristol-Myers Squibb Company	Pyridyl-substituted spiro-hydantoin compounds and use thereof
JP2008524331A (ja) *	2004-12-21	2008-07-10	武田薬品工業株式会社	ジペプチジルペプチダーゼ阻害剤
US20080033027A1 (en) *	2005-03-21	2008-02-07	Vicus Therapeutics Spe 1, Llc	Drug combination pharmaceutical compositions and methods for using them
WO2006102476A2 (en) *	2005-03-21	2006-09-28	Vicus Therapeutics Spe 1, Llc	Compositions and methods for ameliorating cachexia
US20090117197A1 (en) *	2005-03-21	2009-05-07	Vicus Therapeutics Llc	Compositions and methods for ameliorating cachexia
US7709517B2 (en)	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
WO2007027532A2 (en) *	2005-08-29	2007-03-08	Merck & Co., Inc.	Niacin receptor agonists, compositions containing such compounds and methods of treatment
CA2622472C (en) *	2005-09-14	2013-11-19	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors for treating diabetes
US20070060528A1 (en) *	2005-09-14	2007-03-15	Christopher Ronald J	Administration of dipeptidyl peptidase inhibitors
TW200745079A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
TW200745080A (en) *	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
CN101360723A (zh) *	2005-09-16	2009-02-04	武田药品工业株式会社	制备嘧啶二酮衍生物的方法
WO2007047146A2 (en) *	2005-10-11	2007-04-26	Intermune, Inc.	Inhibitors of viral replication
US8926990B2 (en)	2009-10-13	2015-01-06	Rutgers, The State University Of New Jersey	Treatment and diagnosis of inflammatory disorders and HIV
CN101032483B (zh) *	2006-03-09	2011-05-04	陈德桂	调节雄激素受体活性的乙内酰脲衍生物及其应用
PT2656841T (pt)	2006-03-27	2016-09-28	Univ California	Modulador do recetor de androgénios para o tratamento de cancro da próstata e doenças associadas ao recetor de androgénios
WO2007112368A1 (en) *	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Preparation of (r)-3-aminopiperidine dihydrochloride
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
KR101600230B1 (ko)	2006-03-29	2016-03-04	더 리전트 오브 더 유니버시티 오브 캘리포니아	디아릴티오히단토인 화합물
US7740064B2 (en)	2006-05-24	2010-06-22	Baker Hughes Incorporated	System, method, and apparatus for downhole submersible pump having fiber optic communications
KR20090040478A (ko)	2006-08-24	2009-04-24	노파르티스 아게	２-(피라진-２-일)-티아졸 및 ２-(１Ｈ-피라졸-３-일)-티아졸 유도체, 및 대사, 심혈관 및 기타 장애의 치료를 위한 스테아로일-ＣｏＡ 데새투라제(ＳＣＤ) 억제제로서의 관련 화합물
AU2007296556B2 (en) *	2006-09-13	2013-09-19	Takeda Pharmaceutical Company Limited	Use of 2-6- (3-Amino-piperidin-1-yl) -3-methyl-2, 4-dioxo-3, 4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
US8324383B2 (en)	2006-09-13	2012-12-04	Takeda Pharmaceutical Company Limited	Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
CN101516877B (zh)	2006-09-22	2013-09-11	诺瓦提斯公司	杂环有机化合物
TW200838536A (en) *	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AU2007336238A1 (en)	2006-12-20	2008-06-26	Novartis Ag	2-substituted 5-membered heterocycles as SCD inhibitors
JPWO2008090944A1 (ja)	2007-01-25	2010-05-20	武田薬品工業株式会社	スピロ環化合物
US8575167B2 (en)	2007-02-06	2013-11-05	Takeda Pharmaceutical Company Limited	Spiro compounds having stearoyl-CoA desaturase action
US8093236B2 (en)	2007-03-13	2012-01-10	Takeda Pharmaceuticals Company Limited	Weekly administration of dipeptidyl peptidase inhibitors
WO2009011261A1 (ja) *	2007-07-19	2009-01-22	Tokuyama Corporation	ヒダントイン環を有する化合物及びその製造方法
WO2009054914A1 (en) *	2007-10-19	2009-04-30	Sarcode Corporation	Compositions and methods for treatment of diabetic retinopathy
EP2220050A2 (de)	2007-10-26	2010-08-25	The Regents Of The University Of California	Diarylhydantoinverbindungen als androgenrezeptormodulatoren
WO2009061830A1 (en) *	2007-11-06	2009-05-14	Massachusetts Eye & Ear Infirmary	Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
JP5384733B2 (ja)	2009-06-02	2014-01-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	６，７−ジヒドロ−５Ｈ−イミダゾ［１，２−ａ］イミダゾール−３−カルボン酸アミドの誘導体
BR112012004919A2 (pt)	2009-09-04	2019-09-24	Univ Vanderbilt	potencializadores alostericos de mglur4, composição e metodos de tratamentos de disfunção neurologica
ES2668380T3 (es)	2010-02-16	2018-05-17	Aragon Pharmaceuticals, Inc.	Moduladores de receptores de andrógenos y sus usos
ES2779748T3 (es)	2012-08-23	2020-08-19	Janssen Biopharma Inc	Compuestos para el tratamiento de infecciones víricas por paramixovirus
SI3305285T1 (sl)	2012-09-26	2021-03-31	Aragon Pharmaceuticals, Inc.	Anti-androgeni za zdravljenje proti kastraciji odpornega ne-metastatskega raka
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
CN114716426A (zh)	2013-08-21	2022-07-08	詹森生物制药有限公司	抗病毒化合物
KR20160133004A (ko) *	2014-04-04	2016-11-21	엑스-알엑스, 인크.	오토탁신의 치환된 스피로시클릭 억제제
US10112939B2 (en)	2014-08-21	2018-10-30	Bristol-Myers Squibb Company	Tied-back benzamide derivatives as potent rock inhibitors
MA41614A (fr)	2015-02-25	2018-01-02	Alios Biopharma Inc	Composés antiviraux
TWI726969B (zh)	2016-01-11	2021-05-11	比利時商健生藥品公司	用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US10610520B2 (en)	2016-03-31	2020-04-07	Takeda Pharmaceutical Company Limited	Heterocyclic compound
JOP20200076A1 (ar)	2017-10-16	2020-04-30	Aragon Pharmaceuticals Inc	مضادات أندروجين لعلاج سرطان البروستاتا غير النقيلي المقاوم للاستئصال
US20240116864A1 (en) *	2020-12-24	2024-04-11	Orn Almarsson	Xanthophyll derivatives
CN115536494B (zh) *	2022-10-31	2023-12-01	苏州诚和医药化学有限公司	1-(4-溴苯基)-1,4-丁二醇的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1331757C (en) *	1988-02-29	1994-08-30	Janssen Pharmaceutica Naamloze Vennootschap	5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols
US5346913A (en) *	1992-05-26	1994-09-13	Rohm And Haas Company	N-iodopropargyl hydantoin compounds, compositions, preparation, and use as antimicrobial agents
FR2694290B1 (fr) *	1992-07-08	1994-09-02	Roussel Uclaf	Nouvelles phénylimidazolidines éventuellement substituées, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant.
TW521073B (en) *	1994-01-05	2003-02-21	Hoechst Marion Roussel Inc	New optionally substituted phenylimidazolidines, their preparation process, their use as anti-androgenic agent and the pharmaceutical compositions containing them
FR2741342B1 (fr) *	1995-11-22	1998-02-06	Roussel Uclaf	Nouvelles phenylimidazolidines fluorees ou hydroxylees, procede, intermediaires de preparation, application comme medicaments, nouvelle utilisation et compositions pharmaceutiques
WO2002096426A1 (en)	2001-05-25	2002-12-05	Bristol-Myers Squibb Company	Hydantion derivatives as inhibitors of matrix metalloproteinases

2002
- 2002-09-30 RS YU26604A patent/RS26604A/sr unknown
- 2002-09-30 GE GE5595A patent/GEP20063767B/en unknown
- 2002-09-30 CA CA002462112A patent/CA2462112A1/en not_active Abandoned
- 2002-09-30 NZ NZ531870A patent/NZ531870A/en unknown
- 2002-09-30 IL IL16099002A patent/IL160990A0/xx unknown
- 2002-09-30 HU HU0402338A patent/HUP0402338A3/hu unknown
- 2002-09-30 BR BR0213025-4A patent/BR0213025A/pt not_active IP Right Cessation
- 2002-09-30 MX MXPA04002993A patent/MXPA04002993A/es unknown
- 2002-09-30 CN CNA028238540A patent/CN1596253A/zh active Pending
- 2002-09-30 JP JP2003532494A patent/JP4394442B2/ja not_active Expired - Fee Related
- 2002-09-30 WO PCT/US2002/031283 patent/WO2003029245A1/en active IP Right Grant
- 2002-09-30 KR KR10-2004-7004778A patent/KR20040041649A/ko not_active Application Discontinuation
- 2002-09-30 EP EP02800414A patent/EP1432700B1/de not_active Expired - Lifetime
- 2002-09-30 DE DE60234264T patent/DE60234264D1/de not_active Expired - Lifetime
- 2002-09-30 AR ARP020103695A patent/AR036663A1/es unknown
- 2002-09-30 PL PL02369337A patent/PL369337A1/xx not_active Application Discontinuation
- 2002-09-30 ES ES02800414T patent/ES2339107T3/es not_active Expired - Lifetime
- 2002-09-30 AT AT02800414T patent/ATE447565T1/de not_active IP Right Cessation
- 2002-10-01 PE PE2002000971A patent/PE20030845A1/es not_active Application Discontinuation
- 2002-10-01 US US10/262,182 patent/US6977267B2/en not_active Expired - Lifetime
2004
- 2004-03-24 IS IS7197A patent/IS7197A/is unknown
- 2004-03-31 NO NO20041339A patent/NO20041339L/no not_active Application Discontinuation
- 2004-04-01 HR HR20040311A patent/HRP20040311A2/hr not_active Application Discontinuation
- 2004-05-24 US US10/852,576 patent/US7078420B2/en not_active Expired - Lifetime
- 2004-06-16 US US10/869,289 patent/US20040259897A1/en not_active Abandoned
- 2004-06-16 US US10/869,292 patent/US20050004153A1/en not_active Abandoned
- 2004-08-18 HK HK04106189.4A patent/HK1063467A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
HRP20040311A2 (en)	2005-02-28
HUP0402338A2 (hu)	2005-02-28
US20040259897A1 (en)	2004-12-23
PL369337A1 (en)	2005-04-18
NO20041339L (no)	2004-05-24
EP1432700A1 (de)	2004-06-30
JP2005510476A (ja)	2005-04-21
IS7197A (is)	2004-03-24
KR20040041649A (ko)	2004-05-17
GEP20063767B (en)	2006-03-10
US7078420B2 (en)	2006-07-18
JP4394442B2 (ja)	2010-01-06
PE20030845A1 (es)	2003-10-23
NZ531870A (en)	2005-08-26
NO20041339D0 (no)	2004-03-31
HUP0402338A3 (en)	2008-10-28
EP1432700B1 (de)	2009-11-04
CA2462112A1 (en)	2003-04-10
US20050004153A1 (en)	2005-01-06
DE60234264D1 (de)	2009-12-17
US20040009998A1 (en)	2004-01-15
WO2003029245A1 (en)	2003-04-10
ES2339107T3 (es)	2010-05-17
CN1596253A (zh)	2005-03-16
EP1432700A4 (de)	2004-12-22
MXPA04002993A (es)	2004-07-15
US6977267B2 (en)	2005-12-20
US20040248920A1 (en)	2004-12-09
RS26604A (en)	2006-12-15
HK1063467A1 (en)	2004-12-31
AR036663A1 (es)	2004-09-22
IL160990A0 (en)	2004-08-31
BR0213025A (pt)	2004-10-05

Legal Events

Date	Code	Title	Description
2010-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE447565T1 (de)	2009-11-15	Spiro-hydantoin-verbindungen, die sich als entzündungshemmende mittel eignen
ATE549328T1 (de)	2012-03-15	Aromatisch-heterocyclische verbindungen als entzündungshemmende mittel
ATE445610T1 (de)	2009-10-15	Neue, sich als antiproliferative mittel eignende benzimidazolderivate
IS6971A (is)	2003-09-29	Ný efnasambönd
MXPA03009361A (es)	2004-01-29	Compuestos de urea utilies como agentes anti-inflamatorios.
DE60124296D1 (de)	2006-12-14	Biphenylcarbonsäureamide, die sich als lipidsenker eignen
DE60228493D1 (de)	2008-10-02	Dreiphasige nanoverbundstähle
DE60210598D1 (de)	2006-05-24	3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ATE287405T1 (de)	2005-02-15	5-halogen-6-phenyl-7-fluoroalkylamino- triazolopyrimidine als fungizide
NO20041134L (no)	2004-05-18	Likestromsomformer.
DE60207318D1 (de)	2005-12-22	Festes kosmetisches Mittel
DE50206096D1 (de)	2006-05-11	Substituierte benzoäbüazepin-2-on-verbindungen als schmerzmittel
DE60230470D1 (de)	2009-02-05	Festes kosmetisches Mittel
NO20016398D0 (no)	2001-12-27	Mini-kraftomformer I
DE50213683D1 (de)	2009-08-27	Peltonschaufel
DE50209313D1 (de)	2007-03-08	Selektive arylguanidinpeptide als urokinaseinhibitoren
DE60220799D1 (de)	2007-08-02	Hypoglykämisches mittel
ATE309239T1 (de)	2005-11-15	Aminopyrrol verbindungen als entzündungshemmende wirkstoffe
DE50208676D1 (de)	2006-12-28	Builder-Zusammensetzung
DE60136966D1 (de)	2009-01-22	Pflanzenstärkendes mittel
DE60233727D1 (de)	2009-10-29	Duftstoffe
DK1497256T3 (da)	2010-09-27	Substituerede 1,5-diaminopentan-3-ol-forbindelser
ES1051328Y (es)	2002-11-01	Bañera compacta.
DE60224192D1 (de)	2008-01-31	Antihaemorrhagische, betain-enthaltende zusammenseuzungen
NO20030877D0 (no)	2003-02-25	Vitamin C-blandinger